Publication
Title
Increased CSF -synuclein levels in Alzheimer's disease : correlation with tau levels
Author
Abstract
Background Given the difficult clinical differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α-synuclein as a potential cerebrospinal fluid biomarker (CSF) for synucleinopathies. Methods CSF α-synuclein-140 concentrations were determined by a prototype xMAP bead-based assay (Innogenetics NV, Belgium). In addition, CSF amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau181P) levels were determined. Results CSF α-synuclein levels were higher in AD patients as compared with cognitively healthy controls (P = .019) and patients with synucleinopathies (P < .001). CSF α-synuclein levels were correlated with T-tau (P < .001) and P-tau181P (P < .001) levels in autopsy-confirmed AD patients. A diagnostic algorithm using α-synuclein and P-tau181P discriminated neuropathologically confirmed AD from DLB patients, resulting in sensitivity and specificity values of 85% and 81%, respectively. Conclusion Because CSF α-synuclein levels were significantly higher in AD as compared with synucleinopathies, α-synuclein might have a value as a biomarker for differential dementia diagnosis.
Language
English
Source (journal)
Alzheimer's & dementia. - Place of publication unknown
Publication
Place of publication unknown : 2014
ISSN
1552-5260
Volume/pages
10:5(2014), p. 290-298
ISI
000366828100005
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 20.01.2014
Last edited 20.09.2017
To cite this reference